GSK's Reilly, Two Local Executives Of China Unit Charged With Bribery
This article was originally published in PharmAsia News
Mark Reilly, the British head of GlaxoSmithKline's China unit when it sparked an anti-corruption campaign nearly a year ago has been charged by police of masterminding the bribing of China officials and others.
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.